Fodor A, Brombin C, Mangili P, et al. - This study was intended to present molecular subtype impact on early breast cancer (BCa) patients treated with whole-breast hypofractionated (WBH) adjuvant forward-planned intensity-modulated radiotherapy (F-IMRT) without boost. Researchers included a total of 1,325 patients with this pTis-pT3, pNx-N1aM0 BCa who had undergone breast conservation surgery and were treated with WBHF-IMRT in their institute, to a total dose of 40 Gy/15 fractions, without boost between February of 2009 and May of 2017. Despite MAb therapy in Her2+ patients and CT for triple negative BCa patients, molecular subtypes have a strong impact and could be used as a parameter in deciding the boost prescription. Still, the overall estimated probability of LR within 5 years after WBHF-IMRT without a boost is good (2.2%).